Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Indegene IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 1998 Industry: Business Support Listed Page

Profile
Issue Size --
Profile
Price Range 430  to  452 per share
Profile
Min Investment ₹452
Profile
Lot Size 1
Profile
Face Value ₹2
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Indegene Ltd is a leading global healthcare solutions provider, specializing in digital transformation for the life sciences industry. Founded in 1998, the company offers a comprehensive suite of services including medical and commercialization strategies, multichannel engagement, and data analytics. With a focus on innovation, technology, and deep domain expertise, Indegene helps pharmaceutical, biotechnology, and medical device companies enhance their marketing effectiveness, optimize patient outcomes, and navigate the complexities of healthcare ecosystems. Their solutions span across medical affairs, marketing, sales, and patient support, leveraging advanced analytics and AI-driven insights to drive measurable impact. With a global presence and a commitment to delivering value-driven solutions, Indegene continues to shape the future of healthcare delivery and patient care. Read More

Basic Info

Face Value 2 per share

Price 430  to  452 per share

P/E (x) 26.3

Sales( Cr.) 2839

PAT( Cr.) 407

EPS 17.2

Draft Prospectus --

Exchange BSE-NSE

Promoter

Company Promoters

BCP Topco VII Pte. Ltd

Pre Issue Share Holding 100%

Post Issue Share Holding 63.73%

Listing Details:

Listing Price: 659.7

Listing Gain: 31.48%

Current Price: 521.6

Gain On Issue: 521.6 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date May 06, 2024
Closing Date May 08, 2024
Allotment May 09, 2024
Refund May 10, 2024
Delivery of Shares May 10, 2024
Listing Date May 13, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 33 14,916
Retail (Max) 13 429 193,908
S-HNI (Min) 14 462 208,824
S-HNI (Max) 67 2211 999,372
B-HNI (Min) 68 2244 1,014,288

Objective of the Issue

1. Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc. 2. Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc. 3. General corporate purposes and inorganic growth

Issue

Category Nos Bid Bid (x)
QIB 20373446 3926370513 192.7x
NII 6112034 341723821 55.9x
Retail 14261412 112094698 7.9x
EMP 0 0 0x
Total 40746891 2864506437 70.3x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Indegene Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 234 344 472 475 553 643 966 1665 2306 2590 2839
Other Income 4 3 1 3 7 4 31 26 58 76 107
Total Income 237 347 473 478 560 646 997 1690 2364 2666 2947
Total Expenditure 204 291 402 447 511 499 736 1378 1910 2084 2305
Operating Profit 34 56 71 31 49 147 261 313 454 582 642
Interest 2 2 10 8 6 9 7 6 31 49 22
Depreciation 7 15 19 12 17 19 26 33 60 76 80
Exceptional Income / Expenses 0 0 0 0 0 -44 3 -47 0 2 0
Profit Before Tax 24 38 42 11 26 75 231 226 363 459 539
Provision for Tax 5 3 3 7 12 26 46 64 97 122 133
Profit After Tax 18 35 39 4 14 49 186 163 266 337 407
Adjustments 0 0 0 0 0 -56 -36 2 0 0 0
Profit After Adjustments 18 35 39 4 14 -6 149 165 266 337 407
Adjusted Earnings Per Share 0.9 1.8 2 0.2 0.7 -0.3 7.6 7.5 12 15.2 17

Indegene Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 55 90 131 136 152 -105 325 764 1064 1429 2616
Minority's Interest 0 0 0 0 0 89 9 0 0 0 0
Borrowings 2 2 23 1 8 341 18 11 394 333 0
Other Non-Current Liabilities 2 5 7 7 8 -10 9 69 190 101 56
Total Current Liabilities 111 93 148 164 158 247 199 440 489 611 565
Total Liabilities 170 190 310 308 326 562 559 1284 2137 2475 3236
Fixed Assets 29 33 81 75 104 119 86 138 664 646 678
Other Non-Current Assets 11 20 46 60 37 25 14 17 24 38 29
Total Current Assets 130 137 182 174 185 418 459 1130 1449 1791 2530
Total Assets 170 190 310 308 326 562 559 1284 2137 2475 3236

Indegene Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 7 14 8 15 6 31 174 133 506 74 189
Cash Flow from Operating Activities 13 29 27 24 65 22 172 297 130 508 442
Cash Flow from Investing Activities -6 -17 -77 -21 -19 -19 -24 -160 -893 -327 -683
Cash Flow from Financing Activities -0 -18 57 -12 -21 136 -132 233 333 -66 288
Net Cash Inflow / Outflow 7 -6 7 -9 25 140 16 370 -430 114 47
Closing Cash & Cash Equivalent 14 8 15 6 31 174 133 506 74 189 241

Indegene Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.94 1.82 1.99 0.2 0.71 -0.32 7.58 7.45 12.01 15.17 16.98
CEPS(Rs) 1.33 2.6 2.96 0.82 1.56 3.47 10.71 8.88 14.71 18.59 20.33
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 2
Book NAV/Share(Rs) -1.24 0.55 2.61 2.79 3.55 -5.55 16.23 34.28 47.22 62.96 107.7
Core EBITDA Margin(%) 12.71 15.27 14.87 5.93 7.56 22.34 23.86 17.24 17.17 19.52 18.82
EBIT Margin(%) 11.21 11.87 11 3.93 5.78 13.08 24.67 13.96 17.1 19.62 19.77
Pre Tax Margin(%) 10.2 11.15 8.96 2.28 4.65 11.71 23.95 13.61 15.74 17.71 18.99
PAT Margin (%) 7.85 10.31 8.28 0.84 2.55 7.65 19.22 9.78 11.54 13 14.32
Cash Profit Margin (%) 11.04 14.73 12.33 3.39 5.55 10.65 21.86 11.79 14.13 15.94 17.15
ROA(%) 10.77 19.68 15.64 1.3 4.45 11.08 33.13 17.66 15.56 14.6 14.24
ROE(%) 0 0 126.12 7.55 22.54 0 176.32 30.2 29.5 27.56 20.45
ROCE(%) 31.75 43.74 33.32 8.93 14.82 29.65 68.54 41.09 35.2 30.88 25.24
Receivable days 81.1 66.26 68.79 83.08 66.52 75.45 87.03 79.96 85.94 90.91 89.95
Inventory Days 0 0 0 0 0 0 0 0 0 0 0
Payable days 0 0 0 0 0 0 0 0 0 0 0
PER(x) 0 0 0 0 0 0 0 0 0 0 34.05
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 5.37
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0.35
EV/Net Sales(x) 0.39 0.24 0.29 0.3 0.2 0.42 -0.12 -0.3 0.15 0.1 4.75
EV/Core EBITDA(x) 2.69 1.48 1.93 4.68 2.28 1.84 -0.44 -1.59 0.78 0.44 21
Net Sales Growth(%) 0 47.21 37.33 0.65 16.45 16.2 50.3 72.27 38.54 12.29 9.64
EBIT Growth(%) 0 55.83 27.31 -64.04 71.17 163.05 183.49 -2.5 69.62 28.84 10.49
PAT Growth(%) 0 93.33 10.29 -89.74 251.46 249.16 277.4 -12.31 63.43 26.53 20.79
EPS Growth(%) 0 92.74 9.48 -89.76 250.61 -144.74 2471.42 -1.66 61.24 26.25 11.96
Debt/Equity(x) 0.5 0.16 0.59 0.56 0.46 -4.12 0.08 0.02 0.38 0.29 0
Current Ratio(x) 1.17 1.47 1.23 1.06 1.17 1.69 2.3 2.57 2.96 2.93 4.48
Quick Ratio(x) 1.17 1.47 1.23 1.06 1.17 1.69 2.3 2.57 2.96 2.93 4.48
Interest Cover(x) 11.03 16.61 5.38 2.37 5.11 9.56 34.27 38.98 12.6 10.28 25.51
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 10% 19% 35% 28%
Operating Profit CAGR 10% 27% 34% 34%
PAT CAGR 21% 36% 53% 37%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -11% NA% NA% NA%
ROE Average 20% 26% 57% 40%
ROCE Average 25% 30% 40% 33%

Company Contact Information

Indegene Ltd.

Aspen G4, 3rd Floor Manyata Embassy Business Park Outer Ring Road, Nagavara

IPO Lead Manager(s)

Indegene Ltd.

Citigroup Global Markets India Pvt Ltd.

JP Morgan India Pvt Ltd

Kotak Mahindra Capital Co Ltd

Nomura Financial Advisory & Securities (India) Pvt Ltd.

Registrar Info

Indegene Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!